Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Abbott Banks on EPD, Nutrition Growth to Beat Coronavirus Woes
by Zacks Equity Research
Abbott (ABT) expects to register strong growth for the second half of 2020 within established pharmaceuticals (EPD).
Top Research Reports for Disney, Novo Nordisk & BHP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Novo Nordisk (NVO) and BHP Group (BHP).
Abbott Begins BTK Clinical Trial to Evaluate DRS Therapy
by Zacks Equity Research
Abbott (ABT) aims to provide a new treatment option for patients with CLI BTK, thus eliminating the need for any additional treatment.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $104.16 in the latest trading session, marking a -1.3% move from the prior day.
The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric
3 Coronavirus-Led Threats to MedTech That May Linger
by Urmimala Biswas
Let us delve deeper to get an insight into the not-so-talked-about but intense threats to MedTech.
Medicare Coverage for Libre 2 Boosts Abbott's CGM Prospects
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 2 iCGM is now available to Medicare-eligible diabetic patients via CMS' reimbursement expansion.
The Zacks Analyst Blog Highlights: Verizon Communications, Novartis, Abbott Laboratories, AT&T, Intuitive Surgical and Northrop Grumman
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verizon Communications, Novartis, Abbott Laboratories, AT&T, Intuitive Surgical and Northrop Grumman
The Zacks Analyst Blog Highlights: Abbott Lab, Quidel, Becton, Dickinson and Company, Hologic and Quest Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Lab, Quidel, Becton, Dickinson and Company, Hologic and Quest Diagnostics
Market Waits for Major Economic Data This Week
by Zacks Equity Research
Market Waits for Major Economic Data This Week.
Big Week of Econ Data Starts on a Lull
by Mark Vickery
Although this will be a big week for economic data, today sees nothing new on this front.
Coronavirus Impact on Consumer Behavior
by Sheraz Mian
The need to limit infections from Covid-19 will result in permanent social-distancing regulations that dramatically impact most industries in all countries.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $110.79, marking a -0.45% move from the previous day.
Price War in Coronavirus Test Space to Intensify Thanks to Abbott
by Urmimala Biswas
Most rapid antigen tests in the United States require an additional system, which is making the procedures more costly and complex.
Company News for Aug 28, 2020
by Zacks Equity Research
Companies in the news are: BOX, NTAP, ANF, ABT
Tandem Diabetes' Advanced Insulin Pump Study Results Favorable
by Zacks Equity Research
Per the DCLP5 study, Tandem Diabetes' (TNDM) insulin pump with Control-IQ technology suitable for use in children aged six to 13 years, which has been published in the NEJM.
Top Stock Reports for Verizon, Novartis & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications (VZ), Novartis (NVS) and Abbott Laboratories (ABT).
"Great Reopening" Gets 2 Big Boosts: Fed & Abbott
by Mark Vickery
The reason for this good news comes from two specific areas, both of which hit the news cycle ahead of today's open.
The Zacks Analyst Blog Highlights: QIAGEN, Merit Medical, OPKO, Abbott and Abiomed
by Zacks Equity Research
The Zacks Analyst Blog Highlights: QIAGEN, Merit Medical, OPKO, Abbott and Abiomed
MedTech Lifts S&P 500 Index: 3 Stocks With Upside Potential
by Urmimala Biswas
MedTech stocks play a major role in holding the index up and ending the shortest bear run in the history of S&P 500.
Why Is Abbott (ABT) Up 3.7% Since Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Adobe, Abbott Laboratories, Barrick Gold, HSBC Holdings and Square
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Adobe, Abbott Laboratories, Barrick Gold, HSBC Holdings and Square
Top Analyst Reports for Adobe, Abbott & Barrick Gold
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Adobe Systems (ADBE), Abbott Laboratories (ABT) and Barrick Gold (GOLD).
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Bear of the Day: Penumbra (PEN)
by Kevin Cook
Growth stalls for an innovator in blood clot removal and the deadly shadow of stroke with catheter-based aspiration technologies